Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $48.24, but opened at $51.6950. Zealand Pharma A/S shares last traded at $51.6950, with a volume of 102 shares.
Analyst Ratings Changes
Several analysts have commented on the company. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zealand Pharma A/S currently has a consensus rating of “Hold”.
View Our Latest Analysis on Zealand Pharma A/S
Zealand Pharma A/S Stock Performance
About Zealand Pharma A/S
Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.
Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- Is Quantinuum Emerging as a Leader in the Quantum Race?
- J.M. Smucker’s Rally Nears a Key Test: Is a Full Recovery Ahead?
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
